Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M133,863Revenue $M37,075Net Margin (%)12.3Altman Z-Score2.4
Enterprise Value $M67,814EPS $1.8Operating Margin %17.4Piotroski F-Score7
P/E(ttm)27.4Beneish M-Score-2.7Pre-tax Margin (%)16.1Higher ROA y-yY
Price/Book2.110-y EBITDA Growth Rate %2.7Quick Ratio1.3Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %-2.9Current Ratio1.8Lower Leverage y-yN
Price/Free Cash Flow15.2y-y EBITDA Growth Rate %7.5ROA % (ttm)9.1Higher Current Ratio y-yY
Dividend Yield %3.2PEG--ROE % (ttm)15.8Less Shares Outstanding y-yN
Payout Ratio %84.0Shares Outstanding M2,639ROIC % (ttm)15.6Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYNWQ Managers 2015-03-31 Add0.61%$44 - $51.12
($47.81)
$ 50.736%Add 33.50%3,927,517
SNYJames Barrow 2015-03-31 Reduce-0.04%$44 - $51.12
($47.81)
$ 50.736%Reduce 1.88%30,225,221
SNYHOTCHKIS & WILEY 2015-03-31 Add0.02%$44 - $51.12
($47.81)
$ 50.736%Add 0.77%11,782,180
SNYThird Avenue Management 2015-03-31 Sold Out -0.012%$44 - $51.12
($47.81)
$ 50.736%Sold Out0
SNYDodge & Cox 2015-03-31 Reduce-0.01%$44 - $51.12
($47.81)
$ 50.736%Reduce 0.55%43,034,073
SNYFirst Eagle Investment 2015-03-31 Sold Out -0.0038%$44 - $51.12
($47.81)
$ 50.736%Sold Out0
SNYKen Fisher 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 50.736%Reduce 0.21%13,058,095
SNYMario Gabelli 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 50.736%Reduce 9.53%4,700
SNYCharles Brandes 2015-03-31 Add$44 - $51.12
($47.81)
$ 50.736%Add 0.08%2,573,969
SNYHOTCHKIS & WILEY 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 50.735%Add 18.16%11,692,693
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 50.735%Add 22.12%2,941,923
SNYCharles Brandes 2014-12-31 Add0.21%$44.4 - $55
($48.49)
$ 50.735%Add 14.36%2,571,795
SNYJames Barrow 2014-12-31 Add0.15%$44.4 - $55
($48.49)
$ 50.735%Add 8.87%30,804,459
SNYDavid Dreman 2014-12-31 Buy $44.4 - $55
($48.41)
$ 50.735%New holding1,102
SNYBill Nygren 2014-09-30 Add0.27%$50.89 - $57.29
($53.73)
$ 50.73-6%Add 14.55%5,670,000
SNYFirst Eagle Investment 2014-09-30 Reduce-0.07%$50.89 - $57.29
($53.73)
$ 50.73-6%Reduce 94.39%34,157
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 50.73-4%Reduce 52.34%2,602,503
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 50.73-4%Add 90.38%4,950,000
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 50.730%New holding2,600,000
SNYHOTCHKIS & WILEY 2014-03-31 Add0.75%$47.77 - $53.63
($50.68)
$ 50.730%Add 65.83%9,804,594
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-46.49view
Sanofi10% Owner 2015-01-26Buy647,448$95-46.49view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-45.44view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-24view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67562.71view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
      Mt Stocks Apr 19 2015 
      Scottrade Mar 22 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
      FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
      Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
      The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
      Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 
      Causeway International Value Fund Q4 2014 Commentary Jan 20 2015 

      More From Other Websites
      Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
      Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
      3 Top IBD 50 Stocks Hit New All-Time Highs May 21 2015
      Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog May 21 2015
      Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
      Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
      Genzyme’s Announces Launch of Expression of Hope III Art Exhibit May 20 2015
      Orexigen CEO Pledged To Keep Data Secret, But Not From Himself May 20 2015
      Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog May 19 2015
      MannKind stock jumps on positive report about inhaled insulin May 19 2015
      Amgen cholesterol drug could get EU green light this week May 19 2015
      VCEL: Vericel Is Too Cheap To Ignore May 19 2015
      5 Big Pharma Stocks to Trade for Breakout Gains May 19 2015
      Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the... May 19 2015
      MannKind's Huge Short Interest Sets Up Contrarian's Dream Buy May 19 2015
      Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the... May 18 2015
      Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the... May 18 2015
      5 Things MannKind's Management Wants You to Know May 15 2015
      Sanofi (SNY) Exercises Celiac Disease Program Option - Analyst Blog May 14 2015
      Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog May 13 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK